These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34152055)

  • 21. Efficacy of Tasimelteon (HETLIOZ®) in the Treatment of Jet Lag Disorder Evaluated in an 8-h Phase Advance Model; a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Polymeropoulos CM; Mohrman MA; Keefe MS; Brzezynski JL; Wang J; Prokosch LS; Polymeropoulos VM; Xiao C; Birznieks G; Polymeropoulos MH
    Front Neurol; 2020; 11():611. PubMed ID: 32754110
    [No Abstract]   [Full Text] [Related]  

  • 22. Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance - sensitivity analysis using zopiclone as a positive control: Study Protocol Clinical Trial (SPIRIT Compliant).
    Iwata M; Iwamoto K; Kambe D; Tachibana N; Ando M; Ozaki N
    Medicine (Baltimore); 2020 Mar; 99(12):e19395. PubMed ID: 32195934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.
    van de Loo AJAE; Bervoets AC; Mooren L; Bouwmeester NH; Garssen J; Zuiker R; van Amerongen G; van Gerven J; Singh J; der Ark PV; Fedgchin M; Morrison R; Wajs E; Verster JC
    Psychopharmacology (Berl); 2017 Nov; 234(21):3175-3183. PubMed ID: 28755104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Residual effects of zopiclone on driving performance using a standardized driving simulator among healthy volunteers.
    Iwamoto K; Iwata M; Kambe D; Imadera Y; Tachibana N; Kajiyama Y; Ando M; Ozaki N
    Psychopharmacology (Berl); 2022 Mar; 239(3):841-850. PubMed ID: 35106620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.
    Moline M; Zammit G; Yardley J; Pinner K; Kumar D; Perdomo C; Cheng JY
    Postgrad Med; 2021 Jan; 133(1):71-81. PubMed ID: 33119423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-daily tasimelteon (VEC-162) for jet lag following transmeridian travel: A multicenter, randomized, double-blind, placebo-controlled trial.
    Polymeropoulos CM; Polymeropoulos VM; Czeisler EL; Fisher MA; Smieszek SP; Xiao C; Birznieks G; Polymeropoulos MH
    Front Neurol; 2022; 13():901467. PubMed ID: 36188367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
    Stahl SM
    CNS Spectr; 2014 Dec; 19(6):475-8. PubMed ID: 25422900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls.
    Pearlman EM; Wilbraham D; Dennehy EB; Berg PH; Tsai M; Doty EG; Kay GG
    Hum Psychopharmacol; 2020 Sep; 35(5):e2732. PubMed ID: 32449213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tasimelteon: a selective and unique receptor binding profile.
    Lavedan C; Forsberg M; Gentile AJ
    Neuropharmacology; 2015 Apr; 91():142-7. PubMed ID: 25534555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absolute Bioavailability of Tasimelteon.
    Torres R; Dressman MA; Kramer WG; Baroldi P
    Am J Ther; 2015; 22(5):355-60. PubMed ID: 25658956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tasimelteon for insomnia.
    Lankford DA
    Expert Opin Investig Drugs; 2011 Jul; 20(7):987-93. PubMed ID: 21548834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zopiclone as positive control in studies examining the residual effects of hypnotic drugs on driving ability.
    Verster JC; Spence DW; Shahid A; Pandi-Perumal SR; Roth T
    Curr Drug Saf; 2011 Sep; 6(4):209-18. PubMed ID: 22129315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of armodafinil on simulated driving and alertness in shift work disorder.
    Drake C; Gumenyuk V; Roth T; Howard R
    Sleep; 2014 Dec; 37(12):1987-94. PubMed ID: 25325498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring.
    Staner L; Ertlé S; Boeijinga P; Rinaudo G; Arnal MA; Muzet A; Luthringer R
    Psychopharmacology (Berl); 2005 Oct; 181(4):790-8. PubMed ID: 16025317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of driving simulator performance with real driving after alcohol intake: a randomised, single blind, placebo-controlled, cross-over trial.
    Helland A; Jenssen GD; Lervåg LE; Westin AA; Moen T; Sakshaug K; Lydersen S; Mørland J; Slørdal L
    Accid Anal Prev; 2013 Apr; 53():9-16. PubMed ID: 23357031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study.
    Leufkens TR; Ramaekers JG; de Weerd AW; Riedel WJ; Vermeeren A
    Psychopharmacology (Berl); 2014 Jul; 231(14):2785-98. PubMed ID: 24458443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance.
    Verster JC; Volkerts ER; Schreuder AH; Eijken EJ; van Heuckelum JH; Veldhuijzen DS; Verbaten MN; Paty I; Darwish M; Danjou P; Patat A
    J Clin Psychopharmacol; 2002 Dec; 22(6):576-83. PubMed ID: 12454557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers.
    Möller HJ; Volz HP; Seifritz E; Müller H; Kenntner-Mabiala R; Kaussner Y; Schoch S; Kasper S
    J Psychiatr Res; 2021 Apr; 136():543-551. PubMed ID: 33221027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype.
    Ramaekers JG; Conen S; de Kam PJ; Braat S; Peeters P; Theunissen EL; Ivgy-May N
    Psychopharmacology (Berl); 2011 May; 215(2):321-32. PubMed ID: 21246188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone.
    Boyle J; Trick L; Johnsen S; Roach J; Rubens R
    Hum Psychopharmacol; 2008 Jul; 23(5):385-97. PubMed ID: 18350566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.